Jade Biosciences Inc JBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
-
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
-
Jade Biosciences to Participate in Upcoming Conferences
-
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $14.91
- Day Range
- $14.54–15.00
- 52-Week Range
- $8.36–28.00
- Bid/Ask
- $13.50 / $15.98
- Shares Outstanding
- 63.60M
- Market Cap
- $927.89M
- Volume/Avg
- 634,377 / 897,393
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 55
- Website
- https://www.jadebiosciences.com
Valuation
|
Metric
|
JBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
JBIO
|
|---|---|
Quick Ratio | 14.61 |
Current Ratio | 14.93 |
Interest Coverage | — |
Quick Ratio
JBIO
Profitability
|
Metric
|
JBIO
|
|---|---|
Return on Assets (Normalized) | −37.81% |
Return on Equity (Normalized) | −40.88% |
Return on Invested Capital (Normalized) | −44.79% |
Return on Assets
JBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Y<%%y# | LOCK|L@&F@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g?m!q&K | LOCK|?KJZX | $83B | |||
| Moderna Inc
MRNA
| LOCK|tFl%y& | LOCK|CM | $80B | |||
| argenx SE ADR
ARGX
| LOCK|z#d^!d | LOCK|RZw | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^!P<m$ | LOCK|TCv | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d^zC<^ | LOCK|s#pCK | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$g>d>mV | LOCK|tC!j | $28B | |||
| Incyte Corp
INCY
| LOCK|>@?wHM | LOCK|Km? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|bYX?@N# | LOCK|mZ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j%V@!n | LOCK|>< | $14B |
United States